Context. Mutations in melanocortin receptor (MC4R) are the most frequent cause of monogenic obesity in children of European ancestry, but little is known about their prevalence in children from minority populations in the United States.
Introduction
The leptin melanocortin axis plays a crucial role in weight regulation, with mutations in gene members being identified as causal for human monogenic obesity (1) . The melanocortin 4 receptor (MC4R), which is most abundantly expressed in the paraventricular nucleus of the hypothalamus, is the sensor for orexogenic, as well as anorexogenic, signals in this pathway (2) . Binding of alphamelanocyte stimulating hormone (a-MSH) to the G-protein coupled receptor MC4R induces satiety. Mutations in the MC4R gene and genes encoding its trafficking pathway have been identified as the most common cause of monogenic obesity in children of European ancestry, with prevalence estimates ranging from 1.5 to 5.8%, mostly comprised of mutations in MC4R (3) (4) (5) .
Individuals with MC4R mutations have been reported to have significant hyperphagia and early onset of obesity, even in the heterozygous state (3) (4) (5) .
While the obesity epidemic has disproportionately affected non-Hispanic African-American and Hispanic youth in the United States (6) , little is known about the prevalence of MC4R mutations in children of these ethnicities. In a recently published study of 25 unrelated Afro-Caribbean children with obesity from the Guadeloupe Island, one 11.8 year-old boy had a p. Ile301Thr mutation in MC4R (7) , while in a study of South African adults of mixed ancestry that included 63% Black Africans (n = 187), 2.6% harbored a rare MC4R variant (8) . These studies provide early clues on the expected prevalence of MC4R variants in children of non-European ancestry.
In this study, we catalog the frequency of MC4R mutations in children with severe early onset obesity of African-American and/or Latina ancestry in the United States.
Materials and Methods

Clinical study recruitment
The study cohort was recruited from Boston Children's Hospital (BCH), Children's Hospital of Philadelphia (CHOP) and Columbia University Medical Center (CUMC), under each institution's IRB approval. Informed consent, and where appropriate, assent was obtained prior to enrollment.
The inclusion criteria were presence of severe early onset obesity, defined as body mass index (BMI) > 120% of the 95 th percentile on the CDC 2000 BMI charts for age and sex (BMI95pct) (9) documented under 6 years of age with no previously known underlying genetic or other pathogenic cause; for the sequencing study reported herein, we focused on children with selfreported African American and/or Latina ancestry with age at recruitment between 2-18 years.
The subjects at BCH were prospectively identified using a validated electronic algorithm designed to identify children with severe obesity (10) , and families were approached in the clinic for recruitment in the weight management and/or primary care clinic under the Genetics of Early Childhood Obesity (GECO) study (n = 225, NCT01998750). In this cohort, 48.4% (n=109) children were of self-reported African American and/or Latina ancestry. The same algorithm was applied to the electronic data warehouse at CHOP to identify children with severe obesity retrospectively.
After filtering biologically implausible data points, and removing individuals with BMI z-score < -5, or obesity duration less than 6 months, or lack of data in early childhood, 1,648 individuals with severe early onset obesity remained in the study. This was followed by analysis of longitudinal BMI trajectory by Super Imposition by Translation and Rotation (SITAR, R version 3.1.3) to generate the size, tempo, and velocity estimates for each individual subject (n=1,120) of selfreported African American ancestry (11) . Children who had the highest velocity of the BMI trajectory and a DNA sample in the institutional biobank (Center for Applied Genomics) (n=157) were prioritized for genetic sequencing. At CUMC, children were recruited from the 110 families attending the Families Improving Health Together (FIT) Program, a New York state supported clinical and research program designed for children with early onset obesity (n=47).
Phenotype data for longitudinal BMI, blood pressure and laboratory studies were extracted from the electronic health records (EHRs). Class of obesity was assigned according to the recent classification of the CDC 2000 BMI growth charts, with Class 2 as 120-140% of BMI95pct and Class 3 > 140% of BMI95pct (9) . No additional clinical studies were performed for the study.
Molecular genetic analyses:
DNA was extracted from the peripheral blood lymphocytes by standard methods or by saliva collection with DNA GenotekÒ kits as per manufacturer's instructions. The coding exon (332 amino acids) and adjacent intronic regions of MC4R were amplified by polymerase chain reaction (PCR) using previously reported primer pairs (12) . The PCR products were purified and directly sequenced using the Big Dye Sequencing kit (Applied Biosystems, Foster City, CA, USA) on an ABI 3100 automated DNA sequencer (Applied Biosystems, Foster City, CA, USA). The chromatograms from the sequencing studies were analyzed using Chromaseq software (v 1.7).
A subset of the samples was sequenced by whole exome sequencing. Library preparation was performed using SureSelect XT Human All Exon V5 kit (Agilent Technologies), and sequencing was performed on a HiSeq platform (Illumina, Inc) as paired-end 2 x 125-bp runs with minimum 20X coverage. The reads were mapped to the human genome assembly (hg19; UCSC browser) using Burrows-Wheeler Alignment (BWA, 0.6.2, http://bio-bwa.sourceforge.net/). Optical and PCR duplicates were marked and removed with Picard. Local realignment of reads in the indel sites and quality recalibration were performed with the Genome Analysis Tool Kit (version 2.1, http://www.broadinstitute.org/gatk/). SNPs and small INDELs were called with GATK UnifiedGenotyper. Initial variants were filtered following GATK best practice by excluding those variants that had: 1) SNPs "QD < 2.0", "MQ < 40.0", "FS > 60.0", "MQRankSum < -12.5", "ReadPosRankSum < -8.0"; 2) Indels "QD < 2.0", "ReadPosRankSum < -20.0", "FS > 200.0". ANNOVAR (version 2-1-2016, http://www.openbioinformatics.org/annovar/) was used to annotate the variants. Variants were additionally filtered to include nonsynonymous, splice site and indel variants with an allele frequency (AF) < 0.001 in Exome Aggregation Consortium (12) .
The variants were confirmed by Sanger sequencing. Testing was also performed in parents of 4 children with the MC4R variant where DNA samples were available.
Functional studies
Selected MC4R variants were functionally characterized in vitro using cell-based assays to determine 1) the cAMP levels upon stimulation with a-MSH as a measure of MC4R signaling activity, and 2) the MC4R surface expression. Both assays were performed in HEK293 cells transiently transfected with either wild-type or mutant MC4R. HEK293 cells were maintained in DMEM (Cat # 11995065; ThermoFisher Scientific) supplemented with 10 % Fetal Bovine Serum µl Opti-MEM I per well. 24 hours after transfection the medium was aspirated, cells were rinsed once in Krebs-Ringer bicarbonate buffer containing glucose (KRBG; Cat # K4002-10X1l; Sigma-Aldrich). a-MSH (Cat # M4135; Sigma-Aldrich), de-solved in KRBG, was added at various concentrations (0, 0.001, 0.01, 0.1, 1, 10, 100 µM). Cells were incubated for 5 min at 37°C. For sample collection, the medium was aspirated, cells were rinsed once with DPBS and 200 µl 0.1 M HCl was added, followed by an incubation at RT for 10 min. Then cells were scraped off with a P1000 pipette and transferred to an Eppendorf tube and placed on ice, followed by vortexing and spinning for 15 min at 4 degrees at high speed. The supernatant was transferred into one precooled Eppendorf tubes (200 µl) and stored at -80 degrees. The ELISA was performed with the cAMP complete ELISA kit (Cat # ADI-900-163; Enzo Life Sciences) according to the manufacturer's guidelines and 100 µl of each sample was used per reaction. For normalization, protein concentration was determined using Pierce™ BCA Protein Assay Kit (Cat # 23225; ThermoFisher Scientific).
2) MC4R surface expression via surface biotinylation: Cells were seeded in 150 mm tissue culture dishes (Cat # 08-772-24; ThermoFisher Scientific) at a concentration of 16.9 x 10 6 ThermoFisher Scientific). Antibody against ADAM17 (Cat # ab2051; Abcam; 1:1,000), using secondary antibody anti-rabbit HRP (1:10,000; Cat # 7074S; Cell Signaling), was used as the loading control for the surface fraction.
Results
This study included a total of 312 unrelated subjects (BCH = 109, CHOP = 157, CUMC = 46). The demographic distribution of the subjects is provided in Table 1 . Briefly, 86% of the children were of self-reported African American and 20% of Latina ancestry, with 50% being female. All participating children had severe early onset obesity (see Methods).
Of the 312 children who underwent sequencing of MC4R, eight individuals were heterozygous for rare MC4R nonsynonymous protein coding variants with minor allele frequency (MAF) < 1%. The variants identified were R7S, F202L (n=2), M215I, G252D, V253I, I269N, and F284I, three of which have not been previously described in the literature (M215I, G252D, F284I). A further fifteen children harbored common (MAF>1%) synonymous or nonsynonymous coding variants (V103I, I198=, Q156=, I251L).
The BMI trajectories of the children carrying these variants did not differ from the rest of the cohort (Figure 1a ), and there was no increase in the height SD when compared with those of comparable obesity without the mutation, unlike prior report (13) (Figure 1 b) . The clinical features of the subjects are summarized in Table 2 . There was no history of consanguinity in any of the families (Fig. 1, c-h ). In the 4 families where parental DNA was available, autosomal dominant inheritance was present in 3 ( Fig. 1c, d and g), while 1 child had a de novo mutation ( Fig.1 e) .
A subset of the study subjects had data for cardiometabolic risk factors: blood pressure (n = 140), hemoglobin A1c (n = 121), lipid panel (n = 111), and liver enzymes (n = 122). The proportion of individuals with diabetes was higher in the subjects with MC4R mutation (12.5% vs 0.8%, p = 0.01), and prediabetes was not different (25% vs 15%, p = 0.45); while the abnormalities in lipid panel and liver enzymes were not different. Blood pressure in the MC4R positive subjects was not lower as previously reported (14); on the contrary, the systolic BP > 95 th percentile for age, gender and height was noted in 2 individuals ( Table 2 ). The proportion of children with age of onset of severe obesity < 2 years was higher in those with MC4R mutation (75% vs 43%, p= 0.07). 174% of BMI95pct). The available growth data demonstrate tall stature (height Z-score 1.80 -2.37 between ages 2.3 -3.1y). At study intake, the only noted medical problem was obesity, and at age 7, she was being treated for type 2 diabetes mellitus requiring insulin. This variant has been reported as pathogenic in heterozygous state in ClinVar and 17/282,740 alleles in gnomAD, primarily in Latino (AFLat 0.0001).
Clinical Features of
p.F202L, 18: 58038977 G>T , c.606 C>A
The subject is a 10-year old African-American female had an increase in BMI after 2 years of age to a maximal observed at 7 years (BMI z =2.63, 132% of BMI95pct). She is noted to be shorter than typical at younger ages (height z = -1.77 at age 3.2 years) that changed to average (height z = -0.41) at age 7 years. Aside from obesity, the only documented co-morbidity was asthma. This Pregnancy was complicated by maternal pre-eclampsia, polyhydramnios and gestational diabetes and the baby was delivered at 34 weeks by cesarean section with a birth weight of 3.4 kg and macrosomia. The child was diagnosed with gastrointestinal reflux, moderate persistent asthma and toe walking. Weight gain was noted at 12 months with BMI of 19.45 kg/m2 and has continued at 3 years of age with BMI 26.3 kg/m2 (BMI z= 4.69, 148% of BMI95pct). Height has been along the 50 th %tile for age. Karyotype and chromosomal microarray are normal with normal DNA methylation studies for Prader Willi and Angelman syndrome. Both parents are obese and mother has undergone vertical sleeve gastrectomy after the birth of the child.
Functional follow-up
To understand the clinical relevance of the identified rare variants, we performed functional assays on four variants, one novel (F284I) one previously characterized but as yet unpublished (M215I) (www.mc4r.uk.org), and one previously characterized and two published V253I and G252S (16) . As the primary signaling pathway for MC4R involves the activation of Gas subunit and, consequently, adenylyl cyclase (17) (18) (19) , we measured the half-maximal effective concentration (EC50) of ligand-induced cyclic AMP (cAMP) in transiently transfected HEK293 cells expressing wild-type or mutant MC4R after exposure to a range of concentrations of endogenous ligand a-MSH (Figure 2 a) . In this experiment, the initiation in activating Gas signaling required 10-fold higher a-MSH concentration in 2 variants --M215I (EC50 ratio 3.9) and G252S (EC50 ratio 5.9) --and 100-fold higher in the F284I variant (EC50 ratio 20.9) compared to the wild-type (WT) MC4R. Of note, none of the tested variants produced a peak cAMP response as high as that achieved with WT MC4R protein, suggesting that even the variants with normal EC50 ratios have a functional defect. Cell surface localization of the receptor in MC4R-expressing HEK293 cells was assessed by biotinylation of MC4R (Figure 2 b, See Methods). Western blot analysis with antibodies against EGFP to detect the MC4R-EGFP fusion protein showed diminished levels for the mutants as compared to WT, suggesting that decreased expression or protein half-life could contribute to the observed in vitro functional defects for all of these variants. For the variant V253I, while the dose response curve was close to normal, the surface expression was nearly absent, emphasizing the defect in surface trafficking.
Discussion
Mutations in the leptin-melanocortin pathway are the best-defined causes of monogenic obesity, of which autosomal dominant mutations in MC4R are the most common. While the prevalence of severe obesity is highest in children from non-European backgrounds, there is little information on the monogenic causes in these populations.
To our knowledge, this cohort of 312 children with severe early onset obesity from selfreported African American and/or Latina ancestry is the largest reported cohort of severely obese children from these populations tested for MC4R variants. Rare pathogenic MC4R variants, shown either by functional testing or previous literature reports, were found in eight (2.6%) children. This prevalence is comparable to that reported in recent studies in children of European ancestry (4, 20) , but lower than that reported by Farooqi et al (5) . There are two prior reports of rare variants in MC4R in individuals of African American descent: in a cohort of 25 children from the Guadeloupe Island in the Caribbean, one 11.8 years old boy with severe obesity (BMI 30.5 kg/m2, BMI z= 2.39), insulin resistance and blood lipid abnormalities was found to have a variant in MC4R, I301T that is absent in gnomAD and ClinVar (7); in a report of 167 adults of African descent in South Africa, Logan et al identified five rare variants (R7H, R165Q, I170V, I198T, F202L, I251V). In gnomAD, low frequency variants in MC4R like I251L and V103I are equally distributed across populations of different ancestries, while some rare variants are more frequently seen in individuals of African descent such as N240S (AFAfr 0.002) , F202L (AFAfr 0.009), R7H (AFAfr 0.0004); or Latino L304F (AFLat 0.0003), T276C (AFLat 0.0004), Ile269Asn (AFLat 0.0073), A259V (AFLat 0.0002), T150I (AFLat 0.0005) or East Asian such as M218T (AFEastAs 0.0005), Y35C (AFEastAs 0.001). These data and our results suggest that the repertoire and distribution of rare functional variants in MC4R in obese individuals of African American and/or Latina ancesty differ from those seen in the studies of individuals of European ancestry.
Our sample is enriched for severe early onset obesity (BMI > 120% of BMI95pct with an onset of obesity prior to 6 years of age), and the onset of obesity in most children with the MC4R mutations was prior to 2 years of age, similar to other recent reports (21, 22) . We did not observe any differences in the BMI trajectories of the children with the mutation in our cohort. This observation is in keeping with the finding by Kohldorf et al, where they observed a much higher BMI at an early age in children with LEP and LEPR mutations, as compared to those with MC4R (21) . Additionally, we did not observe differences in stature of the individuals with or without the mutations. It is possible that this phenotype is more likely to be observed later in life, or is different across ancestries, or that we are insufficiently powered to observe small differences in height.
Overall, the MC4R gene has been extensively studied, and the recently curated atlas of human MC4R variants (www.mc4r.uk.org) has provided a valuable resource to review the functional relevance of rare variants. In this study, three out of eight (38%) of the variants that we observed (M215I, G252D, F284I) had not been previously described in the literature or in publicly available clinical resources for genetic variants (www.clinvar.org), likely reflecting both increased genetic diversity in children across different ancestry/ethnicity as well as substantial allelic heterogeneity for pathogenic variants in this gene.
In this cohort of severe early onset obesity, none of the enrolled patients had undergone clinical genetic testing for MC4R despite their extreme phenotype seen at an early age. With the advent of safer melanocortin agonist therapies that have been used in patients with POMC, LEPR and MC4R mutations (23, 24) , and the increasing focus on personalized medicine, clinical genetic testing of children with severe early onset obesity is becoming increasingly relevant. Studies on the relationship between genetic and phenotypic variation have been historically carried out on people of European ancestry, with much lower representation of other ancestries/ethnicities. Appropriately, attention is increasingly being paid to the valuable insights that can be gleaned from studies in genetically diverse populations. The clinical role for genetic testing in severe, early onset obesity has been discussed in the guidelines for the management of obesity in children by the Endocrine Society (25) , and we agree that, where indicated, opportunities for testing be made available across the wide range of affected children. Specifically, in order to interpret genetic testing in the populations most affected, it will be critical to have allele frequency and functional data on variants from children of diverse backgrounds. a: Dose response curves (DRC) for the tested MC4R mutants along with WT MC4R as the positive control and mock as the negative control in HEK-293 cellular overexpression system. The DRCs are shifted to the right for all the mutants, and statistically different in all tested variants except V253I. b: EC50 for optimal cAMP response measured by ELISA. All variants except V253I have p-value < 0.05 when compared to WT. c: Western blot gel of the surface expression of MC4R and ADAM17 protein in HEK-293 cells measured by surface biotinylation. All mutants have lower expression of the protein compared to WT. d: Quantitative measurement of the ratio of EGFP/ADAM17 protein expression using ImageJ software for surface expression of the protein. All mutants were significantly lower than WT.
